Loading...

Brilliant Violet 785™ anti-human CD19 Antibody

Pricing & Availability
Clone
HIB19 (See other available formats)
Regulatory Status
RUO
Workshop
V CD19.11
Other Names
B4
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
HIB19_BV785_061412
Human peripheral blood lymphocytes were stained with CD3 FITC and CD19 (clone HIB19) Brilliant Violet 785™.
  • HIB19_BV785_061412
    Human peripheral blood lymphocytes were stained with CD3 FITC and CD19 (clone HIB19) Brilliant Violet 785™.
See Brilliant Violet 785™ spectral data
Cat # Size Price Quantity Check Availability Save
302239 25 tests 172€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302240 100 tests 340€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD19 is a 95 kD type I transmembrane glycoprotein also known as B4. It is a member of the immunoglobulin superfamily expressed on B-cells (from pro-B to blastoid B cells, absent on plasma cells) and follicular dendritic cells. CD19 is involved in B cell development, activation, and differentiation. CD19 forms a complex with CD21 (CR2) and CD81 (TAPA-1), and functions as a BCR co-receptor.

Product Details
Technical data sheet

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections8 and blocking of B cell proliferation. Clone HIB19 is not recommended for formalin-fixed paraffin-embedded sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302267 & 302268).

 

Clone HIB19 partially blocks anti-human CD19 clones 4G7 and SJ25C1 staining based on in-house testing

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  3. Bradbury L, et al. 1993. J. Immunol. 151:2915.
  4. Joseph A, et al. 2010. J. Virol. 84:6645. PubMed
  5. Wang X, et al. 2010. Haematologica. 95:884. (FC) PubMed
  6. Walker JD, et al. 2009. J. Immunol. 182:1548. (Block) PubMed
  7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  8. Hansen A, et al. 2002. Arthritis Rheum. 46:2160. (IHC)
  9. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  10. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations
  1. Garfall AL, et al. 2018. JCI Insight. 3. PubMed
  2. Friedensohn S, et al. 2018. Front Immunol. 9:1401. PubMed
  3. Arce Vargas F et al. 2018. Cancer cell. 33(4):649-663 . PubMed
  4. Costa A et al. 2018. Cancer cell. 33(3):463-479 . PubMed
  5. Adachi Y, et al. 2019. Nat Commun. 10:3883. PubMed
  6. Meehan S, et al. 2019. Commun Biol. 2:229. PubMed
  7. Ruella M, et al. 2018. Nat Med. 24:1499. PubMed
  8. Onodera T, et al. 2019. J Immunol. 203:3282. PubMed
  9. Fajgenbaum DC, et al. 2019. J Clin Invest. 130:4451. PubMed
  10. Lindner JM, et al. 2019. Immunity. 50:668. PubMed
  11. Antonucci L, et al. 2020. Journal of Immunology Research. 3257.929861. PubMed
  12. Tran TM, et al. 2020. Immunity. 51(4):750-765. PubMed
  13. Brown CC, et al. 2020. Cell. 179(4):846-863.e24.. PubMed
  14. Tauriainen J, et al. 2017. Sci Rep. 7:40354. PubMed
  15. Laing AG, et al. 2020. Nat Med. 26:1623. PubMed
  16. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
  17. Maat H, et al. 2021. iScience. 24(5):102435. PubMed
  18. Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed
  19. Chung SH, et al. 2021. Hum Gene Ther. 32:682. PubMed
  20. Combes AJ, et al. 2021. Nature. 591:124. PubMed
  21. Kim ST, et al. 2021. J Immunother Cancer. 9:. PubMed
  22. Vardam-Kaur T, et al. 2021. Oncotarget. 12:2051. PubMed
  23. Lucas C, et al. 2021. Nature. Online ahead of print. PubMed
  24. Vikkurthi R, et al. 2022. Nat Microbiol. 7:974. PubMed
  25. Kroloff M, et al. 2022. J Immunother Cancer. 10:. PubMed
  26. Ye Y, et al. 2022. Nat Commun. 13:6458. PubMed
  27. Xu C, et al. 2022. iScience. 25:105123. PubMed
  28. Asashima H, et al. 2023. Cell Rep. 42:111895. PubMed
  29. Meyer S, et al. 2023. Cell Rep. 42:111995. PubMed
  30. Freitag PC, et al. 2023. Mol Ther Methods Clin Dev. 29:120. PubMed
RRID
AB_11218596 (BioLegend Cat. No. 302239)
AB_2563442 (BioLegend Cat. No. 302240)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 95 kD
Distribution

B lineage (except plasma cells), follicular dendritic cells

Function
B cell activation and differentiation
Ligand/Receptor
Forms complex with CD21 (CR2) and CD81 (TAPA-1), BCR coreceptor
Cell Type
B cells, Dendritic cells
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Tedder T, et al. 1994. Immunol. Today 15:437.
2. Bradbury L, et al. 1993. J. Immunol. 151:2915.

Gene ID
930 View all products for this Gene ID
UniProt
View information about CD19 on UniProt.org
Go To Top Version: 2    Revision Date: 12.18.2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account